You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulpiride
Accession NumberDB00391  (APRD00032)
TypeSmall Molecule
GroupsApproved
Description

A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
(+-)-Sulpiride
5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
Levosulpirida
Levosulpiride
Levosulpiridum
N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
Sulpirid
Sulpirida
Sulpiridum
Sulpyrid
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BosnylNot Available
DogmatilNot Available
DogmatylNot Available
DolmatilNot Available
EglonylNot Available
EspirideNot Available
MeresaNot Available
ModalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7MNE9M8287
CAS number15676-16-1
WeightAverage: 341.426
Monoisotopic: 341.140926929
Chemical FormulaC15H23N3O4S
InChI KeyInChIKey=BGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Salicylamide
  • Benzenesulfonamide
  • Benzoic acid or derivatives
  • Benzamide
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationSulpiride is indicated for the treatment of schizophrenia.
PharmacodynamicsSulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.
Mechanism of actionIn contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.
Related Articles
AbsorptionSulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life6 to 8 hours
ClearanceNot Available
ToxicitySulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9444
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7319
P-glycoprotein inhibitor INon-inhibitor0.857
P-glycoprotein inhibitor IINon-inhibitor0.8994
Renal organic cation transporterNon-inhibitor0.7685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.54
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9656
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9409
Ames testNon AMES toxic0.6229
CarcinogenicityNon-carcinogens0.7139
BiodegradationNot ready biodegradable0.8542
Rat acute toxicity1.8612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8546
hERG inhibition (predictor II)Inhibitor0.549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178 dec °CPhysProp
water solubility2280 mg/LNot Available
logP0.57HOEGBERG,T ET AL. 1986
Caco2 permeability-6.16ADME Research, USCD
pKa9.12EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability36.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AL07N05AL01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
AclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.
Aluminum hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.
AmitriptylineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Amitriptyline.
AmoxapineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Amoxapine.
AmphetamineSulpiride may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Sulpiride.
AtropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atropine.
AzelastineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Azelastine.
BenzatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benzatropine.
BenzphetamineSulpiride may decrease the stimulatory activities of Benzphetamine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sulpiride.
BrompheniramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Brompheniramine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.
CabergolineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.
Calcium carbonateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium carbonate.
CarbinoxamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Carbinoxamine.
CetirizineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cetirizine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.
ChlorphenamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Sulpiride.
ClemastineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Clemastine.
ClomipramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Clomipramine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.
CyclizineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclobenzaprine.
CyclopentolateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclopentolate.
CyproheptadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyproheptadine.
DarifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.
DesipramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desipramine.
DesloratadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.
Dexchlorpheniramine maleateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexchlorpheniramine maleate.
DextroamphetamineSulpiride may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.
DicyclomineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.
DigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.
DimenhydrinateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dimenhydrinate.
DiphenhydramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Diphenhydramine.
DisopyramideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Disopyramide.
DonepezilDonepezil may increase the central neurotoxic activities of Sulpiride.
DoxepinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Doxepin.
DoxylamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Doxylamine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sulpiride.
Etacrynic acidThe risk or severity of adverse effects can be increased when Ethacrynic acid is combined with Sulpiride.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.
FesoterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.
FexofenadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fexofenadine.
FlavoxateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Flavoxate.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sulpiride.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sulpiride.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.
GalantamineGalantamine may increase the central neurotoxic activities of Sulpiride.
GlycopyrroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Glycopyrrolate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.
HomatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Homatropine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.
HydroxyzineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hydroxyzine.
HyoscyamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hyoscyamine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.
ImipramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Imipramine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.
Ipratropium bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.
IsocarboxazidThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Isocarboxazid.
LevocabastineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levocabastine.
LevocetirizineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levocetirizine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sulpiride.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.
LisdexamfetamineSulpiride may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Sulpiride.
LoratadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Loratadine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.
Magnesium hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium hydroxide.
MaprotilineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Maprotiline.
MeclizineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Meclizine.
MepenzolateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mepenzolate.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.
MethamphetamineSulpiride may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sulpiride.
MethscopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methscopolamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.
MethylphenidateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sulpiride.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Sulpiride.
MoclobemideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Moclobemide.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.
NortriptylineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.
OlopatadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Olopatadine.
OrphenadrineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Orphenadrine.
OxybutyninThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sulpiride.
PhendimetrazineSulpiride may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Phenelzine.
PhentermineSulpiride may decrease the stimulatory activities of Phentermine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.
PizotifenThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pizotifen.
PramipexoleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.
ProcyclidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.
PromethazineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Promethazine.
PropanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propantheline.
ProtriptylineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Protriptyline.
PrucaloprideThe risk or severity of adverse effects can be increased when Prucalopride is combined with Sulpiride.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.
QuinagolideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinagolide.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.
RivastigmineRivastigmine may increase the central neurotoxic activities of Sulpiride.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.
RopiniroleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.
ScopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.
Scopolamine butylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine butylbromide.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Sulpiride.
Sodium bicarbonateThe serum concentration of Sulpiride can be decreased when it is combined with Sodium bicarbonate.
SolifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Solifenacin.
SucralfateThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sulpiride.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.
TiotropiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tiotropium.
TolterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tolterodine.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.
TranylcypromineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sulpiride.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.
TrihexyphenidylThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trihexyphenidyl.
TrimethobenzamideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethobenzamide.
TrimipramineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimipramine.
TriprolidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Triprolidine.
TrospiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trospium.
UmeclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Umeclidinium.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Sulpiride.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sulpiride.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sulpiride.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [PubMed:7518029 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [PubMed:19795811 ]
  2. Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [PubMed:18973551 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608 ]
  2. Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23